Marzetti Heads Into Earnings With Shorts Easing but Analysts Cautious

MZTI heads into its November 3 earnings report with a familiar tension: the stock has recovered sharply from its 2026 lows, yet the analyst community has spent the year cutting targets, and a recent food-safety headwind complicates the near-term picture.

The stock closed at $107.81 on October 27, up 1.7% on the week and 7.3% over the past month. That recovery is meaningful given the depth of the year-to-date slide, which earlier ran to roughly 38%. Even with the bounce, the shares trade well below where most analysts are comfortable. The mean price target is $143.60, implying more than 33% upside from current levels, though that gap reflects months of target cuts rather than fresh optimism.

Short positioning is genuinely elevated but softening. At 8.1% of the free float, short interest is large enough to matter, yet it has fallen about 1.5% over the past week and trimmed around 0.5% on October 27 alone. The borrow market tells a different story: availability is extremely loose, with roughly 16 million shares available against 2.2 million short, translating to an availability ratio of 1,238%. Cost to borrow has edged up 25% over the week but remains negligible at 0.47%, far below any threshold that would squeeze existing shorts. The ORTEX short score of 54.7 is mid-range and has drifted slightly lower over the past two weeks, consistent with a position that is being trimmed rather than built. Options are modestly more defensive than usual. The put/call ratio of 0.61 is above its 20-day average of 0.53 but well within one standard deviation, suggesting hedging activity ahead of the print without any particular alarm.

The Street's direction of travel has been uniformly downward, and none of the recent action changes that picture. DA Davidson and Stephens have each cut price targets multiple times across 2026, maintaining Neutral and Equal-Weight ratings respectively. DA Davidson's most recent cut, in late August, brought its target from $168 to $130. Stephens held at $140 after the same earnings release. Both firms left their neutral ratings unchanged, a posture the broader consensus mirrors with a factor score of 50 on analyst recommendation spread. Valuation has drifted higher on the price recovery: the PE ratio has expanded about 0.9 points over 30 days to 15.1 times, and EV/EBITDA has compressed slightly to 9.2 times. One standout factor is the dividend yield rank, which scores in the 92nd percentile of the universe, and the EPS surprise rank at the 84th percentile suggests the company has been consistently beating estimates even as targets fell.

The bull case rests on twelve consecutive quarters of gross margin improvement, a record Q4 gross profit of $114 million, and the Bachan's acquisition growing at above 25%. Bears point to the Cyclospora outbreak that created roughly 250 basis points of sales headwind entering the current quarter, with Olive Garden dressings still down about 6% from pre-outbreak levels. Customer concentration compounds the risk: Chick-fil-A represented 30% of fiscal 2026 Foodservice sales and Walmart 18% of consolidated net sales. Any disruption in either relationship lands heavily on the income statement.

Ownership gives the stock an unusual anchor. John Gerlach holds 24.6% of the company, a stake that limits the free float and likely dampens volatility. BlackRock added 117,615 shares through to September 30, bringing its holding to just over 10%. First Trust added more aggressively, buying 194,252 shares to a 3.7% position. On the insider side, the only open-market transaction in the past 90 days was a sale of 997 shares by the Chief Supply Chain Officer in September, raising around $100,500, a modest disposal that does not read as a strong signal either way. The surrounding August activity was all compensation mechanics, grants and tax withholding, which carry no conviction signal.

Recent earnings reactions have been uniformly negative at the one-day mark. The last two prints produced day-one declines of approximately 2% and 4.5% respectively, with five-day moves of minus 3.4% and minus 3.8%. Whether November 3 follows that pattern depends largely on how management frames the Cyclospora recovery and Q1 margins against a consensus that has spent most of 2026 revising lower.

The November 3 print is therefore less about whether Marzetti can deliver margin improvement and more about whether the food-safety headwind has truly cleared, and how the Bachan's integration reads against the customer-concentration risks the bears have been pricing in all year.